Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Eur Rev Med Pharmacol Sci ; 17(24): 3272-8, 2013 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-24379055

RESUMO

BACKGROUND: Proton pump inhibitors (PPIs) are a major breakthrough in the medical management of gastroesophageal reflux disease (GERD). In several patients with non erosive reflux disease symptoms (NERD) the response to PPIs is partial or limited and symptoms relief needs the administration of additional medications. AIM: The aim of this study was to evaluate the effect of a new medical device, based on an oral fixed combination of hyaluronic acid and chondroitin-sulphate (HA+CS), in a bioadhesive carrier, in adults with symptoms of non erosive gastroesophageal reflux and with a low response to PPIs. PATIENTS AND METHODS: Twenty patients who had experienced heartburn and/or acid regurgitation for at least 3 days during a 7 day run-in period, without endoscopic mucosal breaks, were randomized in a double blind crossover study to receive four daily doses of a fixed oral combination of HA+CS and placebo for 14 days. Relief of cardinal symptoms of GERD was evaluated at the end of each period. RESULTS: A significant greater Sum of Symptoms Intensity Difference, compared to placebo, was observed after HA+CS treatment (-2.7 vs 0.5 - p < 0.01), being both heartburn (-1.6 vs 0.5 - p < 0.03) and acid regurgitation (-1.1 vs 0.1 - p < 0.03) significantly improved by the medical device. A speed of action ≤ 30 min was significantly more frequently reported by patients during HA+CS administration than with placebo (60% vs 30% - p = 0.05). Total disappearance of symptoms was observed in 50% of the patients compared to 10% during placebo administration (p = 0.01 between group comparison). CONCLUSIONS: A fixed combination of HA+CS has demonstrated to be effective in gastroesophageal reflux control, with a rapid onset of action.


Assuntos
Sulfatos de Condroitina/administração & dosagem , Refluxo Gastroesofágico/tratamento farmacológico , Fármacos Gastrointestinais/administração & dosagem , Ácido Hialurônico/administração & dosagem , Administração Oral , Adulto , Idoso , Análise de Variância , Distribuição de Qui-Quadrado , Estudos Cross-Over , Método Duplo-Cego , Esquema de Medicação , Combinação de Medicamentos , Quimioterapia Combinada , Feminino , Refluxo Gastroesofágico/diagnóstico , Antagonistas dos Receptores H2 da Histamina/administração & dosagem , Humanos , Itália , Masculino , Pessoa de Meia-Idade , Inibidores da Bomba de Prótons/administração & dosagem , Fatores de Tempo , Resultado do Tratamento
2.
Minerva Chir ; 52(7-8): 975-7, 1997.
Artigo em Italiano | MEDLINE | ID: mdl-9411303

RESUMO

The authors take the opportunity, on the basis of a clinical case examined, to revise an uncommon disease: neutropenic colitis. In the presence of an acute abdominal pain and tenderness localized at right lower quadrant, in a patient affected by hematologic neoplasm or by a solid tumor, at the end of a chemotherapeutic treatment with absolute residual neutropenia, we would be strongly oriented to neutropenic colitis. The treatment according to the primary disease and to the patient's poor conditions, will be where possible conservative, reserving the surgical approach only for those cases of absolute necessity.


Assuntos
Colite/etiologia , Neutropenia/complicações , Adenocarcinoma/complicações , Adenocarcinoma/tratamento farmacológico , Idoso , Antibióticos Antineoplásicos/uso terapêutico , Antineoplásicos/uso terapêutico , Antineoplásicos Fitogênicos/uso terapêutico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Cisplatino/uso terapêutico , Colite/cirurgia , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Humanos , Neoplasias Pulmonares/complicações , Neoplasias Pulmonares/tratamento farmacológico , Masculino , Mitomicinas/uso terapêutico , Neutropenia/induzido quimicamente , Vindesina/uso terapêutico
3.
Ann Ital Chir ; 63(4): 453-7; discussion 457-8, 1992.
Artigo em Italiano | MEDLINE | ID: mdl-1463257

RESUMO

According to the experience of the authors on a non-selected case report, pharmacologic progresses in the therapy of various aspects of peptic disease permit an ease management also of gastro-esophageal reflux disease. Moreover, endoscopy is the very modern pivot of conservative treatment of more severe complications as strictures are, through repetitive and progressive instrumental dilatations. The surgical treatment of the most severe and intractable eveniences must be chosen for only a low percentage number of patients, after a careful functional analysis of the single case. Very important is the endoscopic and histologic control of Barrett esophagus and severe dysplasia.


Assuntos
Estenose Esofágica/etiologia , Refluxo Gastroesofágico/complicações , Úlcera Péptica/etiologia , Adenocarcinoma/etiologia , Adenocarcinoma/cirurgia , Adenocarcinoma/terapia , Dilatação , Endoscopia , Fístula Esofágica/etiologia , Fístula Esofágica/cirurgia , Fístula Esofágica/terapia , Neoplasias Esofágicas/etiologia , Neoplasias Esofágicas/cirurgia , Neoplasias Esofágicas/terapia , Estenose Esofágica/cirurgia , Estenose Esofágica/terapia , Refluxo Gastroesofágico/cirurgia , Refluxo Gastroesofágico/terapia , Humanos , Úlcera Péptica/cirurgia , Úlcera Péptica/terapia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...